Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of vehicle and PDBAG1 treated TNBC cells

ABSTRACT: To investigate the genes affected by a newly discovered functional peptide, PDBAG1, on triple-negative breast cancer cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE205489 | GEO | 2025/01/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Quantitative proteomics of TNBC

Project description:Quantitative proteomics of triple negative breast cancer patient derived cell lines.

2019-11-25 | PXD013872 | Pride

Expression data for triple-negative breast cancer (TNBC) cells following chemotherapy

Project description:The mechanisms behind drug resistance and sensitivity in breast cancers relies on complex signalling pathways that involve the up or downregulation of certain genes. Many of these genes are involved in adhesion, growth, epithelial/mesenchymal transitions, and apoptosis. We used microarrays to assess differences in gene expression in triple-negative breast cancer cells in response to treatment. We examined the triple-negative human cell line HCC1806 treated with docetaxel or control DMSO. The purpose is to find out the early drug induced changes in this cell line.

2015-07-10 | E-GEOD-70690 | biostudies-arrayexpress

Transcriptome profiling of tumors from Caucasian and African American triple negative breast cancer (TNBC) patients.

2021-04-28 | GSE142731 | GEO

Transcriptome profiling of tumors from Kenyan triple negative breast cancer (TNBC) patients.

Project description:Triple negative breast cancer is an aggressive phenotypic breast cancer characterized by ER negative, PR negative and Her2 negative immunohistochemistry status. We embarked on a study to explore the transcriptome of Kenyan TNBC patients and identify potential biomarkers specific to Kenyan population. The transcriptome sequencing of tumors from Kenyan TNBC patients and comparisons with African American and Caucasian TNBC transcriptomes revealed several interesting targets and dysregulated pathways.

2021-04-28 | GSE142258 | GEO

Primary TNBC tumor in the presence or absence of SHP2

Project description:The first bona fide PTP proto-oncogene was the Src-homology 2 domain-containing phosphatase SHP2 (encoded by PTPN11), an ubiquitously expressed PTP that transduces mitogenic, pro-survival, cell fate and/or pro-migratory signals from numerous growth factor-, cytokine- and extracellular matrix receptors. In malignancies, SHP2 is hyperactivated either downstream of oncoproteins or by mutations.We provide analysis of a primary triple-negative breast tumor grown as xenografts in the presence or absence of SHP2 for 30 days. A primary triple-negative breast tumor (BT8) was transduced with a doxycycline-inducible lentiviral vector expressing a CTRL miR or SHP2 miR1 or SHP2 miR2. Cells from each group were injected in immunodeficient mice and after tumor development, the knockdown of SHP2 was induced for 30 days in vivo. At day 30, tumors were dissected and RNA isolated for gene expression analysis.

2012-01-16 | E-GEOD-35118 | biostudies-arrayexpress

Expression data from triple negative breast cancer-MDA-MB-231 cells treated with vehicle and salvia chinensia benth

Project description:To identify salvia chinensia benths induced transcriptional changes in triple negative breast cancer cell, RNA-sequencing of MDA-MB-231 cells after salvia chinensia benths treantmnent was performed. Differential gene expression analysis resulted in 7582 differentially expressed genes.

2022-08-25 | GSE189547 | GEO

Cisplatin-induced gene expression changes in triple-negative breast cancer (TNBC) cells

Project description:Breast cancers lacking receptors for estrogen, progesterone or HER2 on their cell surface are called triple-negative breast cancers (TNBCs). TNBCs account for ~15-20% of all invasive breast cancers and do not benefit from anti-hormonal or anti-HER2 treatments. Although patients with TNBC can initially respond to chemotherapy, they do have worse overall prognosis compared to other breast cancer subtypes. Unfortunately, TNBCs lack clear targetable ‘driver’ oncogenes. Thus, there is an unmet need for strategies to improve the therapeutic options for these patients. We used microarrays to assess differences in gene expression in triple-negative breast cancer cells in response to the platinum-based chemotherapeutic agent cisplatin. The purpose was to find drug induced changes in gene expression level that could differentiate cisplatin sensitive from cisplatin resistant TNBC cell lines.

2017-08-26 | GSE103115 | GEO

Expression data from Triple Negative Breast Cancer (TNBC) cell lines cultured in 2D and 3D.

Project description:Development of a reliable method for human triple-negative breast cancer organotypic culture: Improving imaging and genomic studies in 3D cultures The primary objectives of this study are to develop an advanced three-dimensional cell culture system to better model the tumor microenvironment in triple-negative breast cancer (TNBC), analyze the differences in molecular and cellular behavior between two-dimensional (2D) and 3D cultures, and investigate the impact of these differences on key oncogenic signaling pathways, specifically PI3K and β-catenin.

2024-09-20 | GSE277405 | GEO

LncRNA expression profile in triple negative breast cancer (TNBC)

Project description:LncRNA expression profile in triple negative breast cancer (TNBC)

| PRJNA656835 | ENA

Expression data from MDA-MB-231 cells treated with vehicle or YW3-56

Project description:PAD4 is overexpressed in many cancer cells. We developed PAD inhibitors that efficiently inhibit the cancer cell growth. One inhibitor YW3-56 could efficently induce cell death of triple negative breast cancer MDA-MB-231 cells. We used microarray to detail the global gene expression of MDA-MB-231 before and after YW3-56 treatment and identify significant up-regulated or down-regulated genes by YW3-56

2015-05-21 | GSE46590 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data